|
Luvox
Canada. "Dear Healthcare Professional" letters have been issued by the manufacturers of seven selective serotonin reuptake inhibitors SSRIs ; and other newer antidepressants, in conjunction with Health Canada, highlighting important safety information regarding potential behavioural and emotional changes. A new Class warning has been incorporated into the labelling for mirtazapine Organon's Remeron RD Remeron ; , 1 ; fluvoxamine Solvay Pharma's Luv0x ; , 2 ; venlafaxine Wyeth Pharmaceutical's Effexor.
Luvox thyroid
SEMINARS S77 S78 S79 S80 S81 S82 S83 S84 S85 S86 S87 Pipeline Programs for Rural Family Medicine: Two-Model Programs-NH Dartmouth and Penn State Susan Linsey MA, Donald Kollisch MD, Maren Flynn MSII, Ivy Ryan MSII, Dennis Gingrich, MD Guidelines for Putting Complementary and Alternative Medicine CAM ; into Practice Cynthia Paige MD Communication Between Colleagues in Different Disciplines in a Community Family Practice Residency Program David Conway MD, Rocco Ricci BA, MS R ; Who Shaves the Barber: A Lesson for Modern Medicine Mark Foley DO Active Learning: Strategies for Maximizing the Student's Experience in a Busy Preceptor's Office Richard Pretorius MD, MPH, Barbara Majeroni MD Clinical Decision Making: Reasoned Process or Shot in the Dark? Donald Woolever MD Procedure World A New Paradigm for Procedural Skills Training Ellen Johnson MD S R ; International Health and Family Medicine: Opportunities for Students and Residents: A View from Eritrea Sallie Rixey, MD, MEd et al Osteopathic Track ; OMT in the Primary Care Setting Amity Rubeor DO, Rocco Caveng DO Developing Patient Advocacy Programs for Medical Students Julie Taylor MD, MSc., Tamara Chang AB, Bonnie Lau AB, David Anthony MD, MSc Vioxx: The Marketing of an Unsafe Drug Bruce Soloway MD.
Benzodiazepines can have bothersome to severe side effects and are addictive. c ; Buspirone BuSpar ; avoids some side effects of the other anxiolytics, including the potential for dependence, but requires days to weeks of use prior to symptom relief. d ; Many antidepressant drugs are now being used to treat anxiety disorders. These include fluoxetine Prozac ; , paroxetine Paxil ; , clomipramine Anafranil ; , fluvoxamine Luvix ; and sertraline Zoloft ; . Human Diversity and Drug Treatment The same psychoactive drug can have significantly different effects in people from different ethnic groups and in men versus women. Some of the ethnic differences may be related to genetically regulated differences in drug metabolism, whereas others may be due to dietary practices. b ; Gender differences in drug response appear related to hormonal or body composition differences. Drugs and Psychotherapy 1. Drug treatments can have serious unpredictable side effects, including dependence and irreversible movement problems. Recently there have been warnings about the danger of suicidal behavior in children and adolescents who are given certain antidepressants, a.
No significant differences in mothers' reported use of alcohol, tobacco, or marijuana between groups, although significantly more women in the exposed group n 8 ; selfreported cocaine use compared to the unexposed group n 0 ; . Two analyses were performed: one assessed infants ever exposed to a TCA or SSRI during pregnancy, and the second compared the effects of exposure during the first 2 trimesters to exposure during the third trimester only. No significant differences were observed between exposed and unexposed infants in the rates of major malformations, minor malformations, developmental delay, head circumference or other neurological disorder in either the TCA or SSRI groups. There were statistically significant differences in gestational age, birth weight, and Apgar scores at 5 minutes between infants exposed to SSRIs and those not exposed. Since differences in birth weights or Apgar scores may be due to differences in rates of prematurity, secondary analyses were done to adjust for gestational age. After this adjustment, infants exposed to SSRIs did not differ significantly in mean birth weight. Analyses of perinatal outcomes according to specific SSRI agent yielded similar results for Paxil, fluoxetine, and sertraline. Exposure to SSRIs during the third trimester was associated with statistically significantly lower Apgar scores. The longterm clinical impact of this difference is not known. Hendrick, et al prospectively followed women who received SSRI antidepressants to determine the incidence of congenital anomalies and neonatal complications after prenatal exposure. 19 ; Birth outcomes were obtained from a review of obstetric and neonatal records of 138 women who were treated with fluoxetine n 73 ; , sertraline n 36 ; , paroxetine n 19 ; , citalopram n 7 ; or Luox fluvoxamine maleate, Solvay ; n 3 ; . Eightyfive of these women received antidepressants during the entire pregnancy and 131 women were receiving the medication at delivery. The incidence of congenital anomalies in this study was 1.4% which is comparable to general population. Four cases 2.9% ; of low birth weight were reported all involved infants who had been exposed to fluoxetine therapy 40 to 80 mg daily ; throughout pregnancy. Nine cases 6.5% ; of preterm births were reported five fluoxetine exposures 6.8% ; , two paroxetine exposures including one birth of twins, 10.5% ; , and two sertraline exposures 5.5% ; . Hostetter et al assessed the medication dosage requirements of SSRIs in pregnant women with a primary diagnosis of major depressive disorder in a naturalistic study. 20 ; These women were followed prospectively through pregnancy at monthly intervals with symptom assessment. Thirtyfour women treated with SSRI monotherapy were included in the final analysis. Of these, 19 women entered the study during their first trimester and 15 entered during their second trimester. These patients received Paxil n 12 ; , sertraline n 13 ; or fluoxetine n 9 ; . Twentytwo of the 34 women 65% ; required an increase in dose to maintain euthymia during pregnancy there was no difference among the 3 SSRIs with respect to dosage adjustment. While the primary purpose of this study was to assess dosage change requirements in these patients, obstetrical outcomes were reported overall. Thirtyone women had normal deliveries of healthy infants. Two women experienced preterm delivery and 1 woman suffered a placental abruption at week 37 with fetal demise. Overall, no significant differences in neonatal outcome were found between the medications. Alwan et al evaluated data from the National Birth Defects Prevention Study, an ongoing case study of risk factors for birth defects, on infants delivered from 19972002 with or without selected major birth defects from 8 US states. 21 ; A total of 9622 infants with selected major birth defects either isolated or multiple ; and 4092 normal controls were identified. Adjusted analyses showed that women who took an SSRI in the period between 1 month before and 3 months after conception were more likely than those who were not exposed to have an infant with anencephaly OR, 2.4 95% CI, 1.1 5.1 ; , craniosynostosis OR, 2.5 95% CI, 1.5 4.0 ; , or omphalocele OR, 2.8, 95% CI 1.3 5.7 ; . When pooling the occurrence of these three defects together, the use of paroxetine OR, 4.2 95% CI, 2.1 8.5 ; or citalopram OR, 4.0 95% CI, 1.3 11.9 ; was reported to be associated with the strongest effect, although fluoxetine and sertraline had a lower confidence bound of 1. For isolated defects, paroxetine was significantly associated with anencephaly OR, 5.1 95%CI, 1.7 ; , omphalocele OR, 8.1 95% CI, 3.1 20.8 ; , with a lower confidence bound of 1 for RVOTO OR, 2.5 95% CI, 1.0 6.0 ; and gastroschisis OR, 2.9 95% CI, 1.0 8.4 ; . Fluoxetine was significantly associated with craniosynostosis OR, 2.8 95% CI, 1.3 6.1 ; and sertraline with anencephaly OR, 3.2 95% CI, 1.1 9.3 ; . The investigators stated that the absolute risks of the three defects anencephaly, omphalocele, and craniosynostosis ; were small compared to baseline risks for all pregnancies and require confirmation by other studies. Wogelius et al performed a populationbased cohort study in 4 Danish counties evaluating the risk of congenital malformations in pregnant women who redeemed a prescription for SSRIs 30 days before conception to the end of the first trimester. 22 ; A total of 1054 women with SSRI prescriptions were 5.
Antidepressants in clinical trials. A large Danish study run by the Danish University Antidepressant Group later confirmed thisxli. This was at a time when the size of the non-hospital depression market still appeared relatively small. It was, therefore, not obvious how a less effective antidepressant, even if it were safer, could be expected to take a significant share in this market. The clinical development of paroxetine accordingly lagged way behind that of Zelmid and Indalpine and considerably behind that of Luvlx and Prozac. Paroxetine ended up being licensed as Paxil in 1993 in the United States and Seroxat in 1992 in the United Kingdom. As part of the effort to make up ground on the others, marketers within what was now SmithKline Beecham coined the acronym SSRI. Compared to the other serotonin reuptake inhibitors, paroxetine was supposedly the selective serotonin reuptake inhibitor the SSRIxlii. The name worked -- too well. It was adopted for the entire group of compounds. In this way, Paxil made Prozac and Zoloft into SSRIs. The idea of an SSRI conveys the impression of a clean and specific drug that would be freer of side effects than the non-selective TCAs. However, selectivity for pharmacologists and selectivity for clinicians meant different things. For pharmacologists, an SSRI might act on every brain system other than the norepinephrine system and therefore might be in this sense an even dirtier drug than any of the TCAs. Clinicians were misled if they thought that selective meant that these drugs only acted on one brain site, but this was exactly what the marketing of these drugs suggested to clinicians. Where Upjohn had targeted OCD in an effort to carve out a distinctive identity for Luvox, SmithKline targeted panic disorder, anxious depressions, generalized anxiety disorder and social phobia. When the company got a license to market Paxil for social phobia, its stock rose; an anti-shyness pill was potentially a huge market. Social phobia had until the 1990s been a condition that was almost unknown in the Western worldxliii. First described in the 1960s at the Institute of Psychiatry in London by Isaac Marks, social phobia presented rarely to clinics. It would be a mistake to think that SmithKline somehow invented social phobia because in the Far East it appears that social phobias are the most common nervous condition. But there is clearly an overlap between social phobia and shyness. As a consequence, there is a real risk that.
Common Categories of Medication continued ; Common Side Effects Sleepiness, lethargy, cognitive impairment, altered gait, seizure breakthrough, and memory loss are typically related to the dosage. Stomach upset especially with Tegretol and Depakote ; , diarrhea, gum growth and swelling with Dilantin ; , weight gain, and hair loss or growth. Liver or kidney dysfunction, hyperactivity, aplastic anemia, allergic response. To obtain this information, talk to the prescribing doctor and the pharmacist who fills the doctor's order. Also ask the pharmacist for a copy of the medication information sheet and have him or her review it with you. Other sources of information include medication reference books from your local library or bookstore. Web sites such as Safemedication or drugconsult also provide medication information. Make sure that you know the answers to all of these questions before you assist an individual in taking a medication. Psychotropics and Psychiatric Disorders and Medications Used for Treatment Psychiatric disorders may involve serious impairments in mental or emotional functioning, which affect a person's ability to perform normal activities and to relate effectively to others. Many individuals with developmental disabilities who also have a psychiatric disorder are treated with psychotropic medications alongside other interventions. Psychotropic medications are central nervous system drugs that affect a person's thinking or feeling. Following is information on three classifications of psychiatric disorders for which individuals might take medication. 1. Mood Disorders Two main types of mood disorders are a. Depression lasting two or more weeks ; , which can mean feelings of hopelessness or even self-destruction; for example, not wanting to eat or get out of bed in the morning. Anti-depressants are used to treat depression. Anti-depressant medications include Tofranil Norpramin Wellbutrin SSRIs selective serotonin reuptake inhibitors--a new class of medications ; include Ouvox fluvoxamine ; Paxil paroxetine ; Prozac fluoxetine ; Zoloft sertraline ; b. Bi-polar Disorder, also called Manic Depression, is often marked by extremes in mood, from elation to deep despair and or manic periods consisting of excessive excitement, delusions of grandeur, or mood elevation. Lithium is used to treat bipolar disorders. Taking this drug requires close monitoring with frequent blood tests. 2. Schizophrenia Schizophrenia can mean hallucinations and sensory misperceptions; delusions strange ideas or false beliefs, including paranoia distorted misinterpretation and retreat from reality; ambivalence; inappropriate affect; and bizarre, withdrawn, or aggressive behavior and keppra.
In addition, it is important to keep a diary or calendar to record the type, severity, and duration of symptoms. Selective serotonin-reuptake inhibitors SSRIs ; are antidepressant drugs that can treat PMDD. SSRIs include fluoxetine Prozac, Sarafem ; , sertraline Zoloft ; , paroxetine Paxil ; , fluvoxamine Luvox ; , and citalopram Celexa ; . SSRIs can relieve physical symptoms, irritability, and tension. In fact, SSRIs appear to relieve PMS-related depression much faster than major depression. Women with PMDD, but without major depression, need only take SSRIs during the 14-day premenstrual period. This approach, called intermittent treatment, causes fewer side effects than when SSRIs are used to treat major depression. Nutritional supplements such as Vitamin B-6, calcium, and magnesium may be recommended. Pain relievers such as aspirin or ibuprofen may be prescribed for headache, backache, menstrual cramping and breast tenderness. Diuretics may be useful for women who experience significant weight gain due to fluid retention. Salpingitis: Infection of the fallopian tubes Sexually Transmitted Diseases: It's scary, but true. Twelve million people are getting STDs each year and two-thirds of these people are teenagers and adults under the age of 25. Sexually transmitted diseases, or STDs, are infections that are spread through sexual contact contact that may be genital, oral or anal. They are caused by either bacteria or viruses and while some can be treated with antibiotics, one is fatalHIV AIDS. Common STDs: Some of the STDs you may have heard about are syphilis, gonorrhea, chlamydia, herpes, and AIDS acquired immunodeficiency syndrome ; , which is caused by HIV. Other types of infections include genital warts, chancroid, and trichomoniasis. Symptoms: Sometimes you can tell if you have an STD and sometimes you cannot. This is because many times the infection doesn't cause any symptoms, especially in women. Another reason is that the signs of the STD, ulcers or breaks in the skin for example, can occur inside the woman's vagina or on the cervix. Symptoms of STDs in women include Sores on or in the vagina, on the labia, on or around the anus or mouth Irregular growths warts ; in the genital area Vaginal discharge may be foul-smelling or discolored ; Vaginal itching Pain on urination or having a bowel movement Pain with intercourse Bleeding or spotting after sexual intercourse Lower abdominal pain Pain or swelling of glands in the groin area Rash Toxic Shock Syndrome TSS ; : This is also called staphylococcal toxic shock syndrome.
R.J. WOODMAN, G.F. WATTS, B.A. KINGWELL, L.J. BEILIN, S.E. HAMILTON, A.M. DART Background decreased arterial compliance is a significant predictor of cardiovascular disease. Systemic arterial compliance is principally determined by aortic compliance but its estimation using the 'area' method Liu et al 1986 ; requires significant technical skill. Commercially available techniques that analyse the pulse pressure waveform are more practicable. Objectives To correlate arterial compliance measured by the 'area' and by commercial methods, and to assess the reproducibility of each technique. Methods Fifteen males with known coronary disease and 15 young healthy volunteers were recruited. Repeat measures were performed randomly and sequentially by the same operator: large and small artery compliance C1 and C2 ; 'CR2000 TradeMark ' ; , augmentation index AI ; , central pulse wave velocity PWV ; and central pulse pressure CPP ; 'Sphygmacor TradeMark ' ; , stiffness index SI ; 'Pulse Trace TM ' ; , and the 'area' method. Reproducibility was assessed by coefficient of variation CV ; , and correlations by linear regression. Results The CV's for C1, C2, AI, PWV, CPP, SI and the area method were 11.3%, 15.6%, 22.4%. and 19.3% respectively. All techniques except SI correlated significantly with the 'area' method r2 0.20 to 0.38, p 0.05 ; . AI, SI, C2 and central PWV were all correlated with each other r2 0.42 to 0.64, p 0.01 ; . Conclusions All commercial methods showed good reproducibility but were weakly associated with an estimate of central aortic compliance. Other properties of the circulation, such as peripheral wave reflectance, may therefore also contribute to AI, C2, PWV and SI. The discriminatory value of these measures for the development of cardiovascular disease merits further examination. Correspondence to R J Woodman University Department of Medicine, University of Western Australia and West Australian Heart Research Institute, Perth, Australia rwoodman cyllene.uwa .au and bupropion.
The Centers for Medicare and Medicaid Services CMS ; has provided the following details on plans for transitioning to the National Provider Identifier NPI ; in the Fee-for-Service Medicare program -- Between May 23, 2005, and Jan. 2, 2006, their claims processing systems will accept an existing legacy Medicare number and reject any claim that includes only an NPI. Beginning Jan. 3, 2006, through Oct. 1, 2006, their systems will accept an existing legacy Medicare number or an NPI as long as an existing legacy Medicare number accompanies it. Beginning Oct. 2, 2006, and through May 22, 2007, they will accept an existing legacy Medicare number and or an NPI. Beginning May 23, 2007, their systems will accept only an NPI.
Various ionization methods were attempted to take the mass spectrum of PNL2, such as EI, FD, and FAB positive and negative ion ; . The molecular ion peak was detected only by negative ion FAB-mass spectrometry with a crown ether, 15-crown-5, added to glycerol as a matrix. The spectrum Fig. 5a ; showed peaks of m z 818 M - H ; , 731 M-CHpCH NH3 ; COOH + H ; , 433 M - OCZoH41CH2CH NH3 ; COOH ; and 224 M - 20C2 H41 - H ; , which were absent in thebackgroundspectrum of the matrix. Fig. 6 shows the FD-mass spectrum of the acid form of PNLP, which showed peaks of m z 733, 653, and 634. The molecular ion was not detected even at the lowest anode temperature 20 mA ; at which any ion peaks appeared. As described previously 25 ; , the difficulty in yielding a molecular ion peak seems to be a specific phenomenon of phosphatidylserine. The masses and intensity of the recorded peaks could be interpreted by pyrolysis of PNL2 at both sides of the phosphodiester bond rather than fragmentation, and masses 733, 653, and 634 could be assigned to diphytanylglycerophosphate + H ; ', diphytanylglycerol + H ; ', and diphytanylglycerol - H, O ; ' and remeron.
Are addressed in rules governing rights, restraint, and abuse and neglect. All of the department's rules are available on request or may be accessed through the internet at mhmr ate.tx . A commenter stated that the subchapter has no clear impetus for revision and only serves to increase regulatory barriers to care. An example is found in the definition of "Refusal to consent to administration of psychoactive medication refusal ; " in 415.3. The commenter referred specifically to subparagraph D ; , which indicates that "The patient either has no response or a noncommittal response after he or she received the standard risk-benefit explanation" should be considered a refusal of treatment by the patient. The commenter noted that this includes patients who have voluntarily admitted themselves to the hospital for treatment. The commenter stated that it is not uncommon for a severely depressed patient to admit himself or herself to a hospital but have great difficulty with active behaviors; in such cases it should be the assumption that a voluntary patient is in the hospital for treatment, not that they are refusing all treatment unless otherwise indicated. The commenter stated that the impact of this kind of rule leads to the increased stress and expense of needless commitment procedures, increased costs for state indigent patients due to the dramatically longer lengths of hospital stays to complete a commitment and obtain an order for medication, and increased costs to the average insured consumer. The department responds that a patient who is incapable of acknowledging consent to medication does not meet criteria for voluntary admission. In both state law and department rules, it has been long established that patients have the right to give or withhold informed consent to treatment. This right relates to specific medications and interventions. Voluntary admission is not a blanket consent to treatment. "Treatment" comprises a wide range of interventions with different risks and benefits that require specific consideration. A commenter stated that the language of 414.412 b ; is confusing and appears to require that court orders for involuntary medications specify individual medications rather than classes under certain circumstances. The commenter stated that this requirement is unrealistic, unnecessary, and would interfere with medical decision-making; further, lack of approval by the Food and Drug Administration FDA ; of a specific indication for a medication should not be a basis for requiring that the medication be specified individually and excluded from a class. The commenter provided several examples of accepted psychiatric treatment involving off-label uses of medications, noting that FDA labeling or lack thereof for specific indications is typically a function of the economics of drug marketing, the remaining patent life of a compound, or the design of studies submitted to the FDA. For example, the most reliable and most widely used mood stabilizer for bipolar maintenance is divalproex Depakote ; , although it lacks the indication for this use. Lamotrogine Lamictal ; , which has the indication, is widely recognized by psychopharmacologists as inferior to Depakote for treating or preventing manic episodes. Alternative and widely used mood stabilizers such as carbamazepine Tegretol ; and oxcarbamazepine Trileptal ; also lack the indication for bipolar maintenance. Some atypical antipsychotics such a ziprasidone Geodon ; and aripiprazole Abilify ; have inherent antidepressant - and probably also mood stabilizing properties but do not have an official FDA indication for these uses. Selective serotonic reuptake inhibitors such as fluoxetine Prozac ; , paroxetine Paxil ; , sertraline Zoloft ; , fluvoxamine Luvox ; and escitalopram Lexapro ; have many properties in common but vary in their approved indications depending on the.
Permanently deny Dr. Rank a license. Dr. Steinbergh stated that she thought that Dr. Rank's objections were very appropriate. Dr. Steinbergh stated that her perception of this case is that Dr. Rank clearly understands what he did. He's clearly remorseful, he knew he was making a mistake. He initially had poor judgment in regard to Patient A, and probably never should have allowed her back into his practice. He clearly understood the first time what he needed to do. Unfortunately, he subsequently accepted her again as a patient because of his expertise in treating headaches. Dr. Steinbergh stated that she does not believe that Patient A was a vulnerable patient, adding that she didn't feel that Dr. Rank took advantage of Patient A. She was a professional woman, his peer, she was a hospital administrator. She came into his practice, and they apparently developed a relationship. It's clear that he should have relieved himself of the responsibility of caring for her, but the record states that they developed a relationship. They did not do anything secretly. They went out socially together, they apparently had intended on a long-term relationship, she told him she was being divorced, he was not married, and they developed a relationship. Dr. Steinbergh stated that it was unfortunate that he made the decision that he made to treat her. Dr. Steinbergh stressed that she did not see this as a vulnerable patient. She didn't see Dr. Rank as clearly violating sexual boundary issues in this particular case, as the Board has seen in so many other cases. Dr. Steinbergh stated that Dr. Rank's objections in that area are appropriate. Dr. Steinbergh referred to Patient B, whom Dr. Rank was treating for headaches. He again used poor judgment in the sense that, when he thought his license was going to be suspended, he gave this patient a note that she could take to other physicians that confirmed what he was prescribing for her and the doses that he was prescribing for her, in hopes of facilitating her care with other physicians. When he was allowed to go on continue to treat her, he erred in not clearing this error. He should have retrieved the note. It was clear that she then went on to other physicians who prescribed medications. So, there was this prescriptive error here, and he recognized that. The Kentucky Board recognized that. Dr. Steinbergh continued that there's also a small case of a C.M.E. issue, where he didn't notify Ohio in his application that Kentucky had disciplined him in regard to mandatory CME that he thought that he had appropriately taken and hadn't. Dr. Steinbergh stated that she feels this is a minor infraction, and it is not of great concern to her. Nevertheless, it is in the record. Dr. Steinbergh stated that she does have an alternative proposal to present to the Board. She stated that, if her proposal meets with the Board's approval, she would ask the Board to table the matter to finalize the language. Dr. Steinbergh stated that she would like to grant Dr. Rank a license. Immediately upon issuance, the license would be suspended for an indefinite period of time, but not less than six months. Conditions for reinstatement would include a requirement that he submit a practice plan for Board approval, with a monitoring physician. There are other steps in that process he must meet, but it's a basic monitoring situation for a period of time. Dr. Steinbergh continued that he would submit to a professional ethics course, a personal ethics course, and a controlled substance prescribing course. He would be and elavil.
Original received October 28, 2006; final version accepted February 9, 2007. From the Departments of Cardiology and Hematology V.D. ; , Tel Aviv Sourasky Medical Center, Tel Aviv, Israel: Tel Aviv University S.S., S.M.-A., S.K., G.K., J.G. ; , Sackler School of Medicine, Tel Aviv, Israel. S.S. and V.D. contributed equally to this study. Correspondence to Jacob George, MD, The Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. E-mail jacobg post.tau.ac.il 2007 American Heart Association, Inc. Arterioscler Thromb Vasc Biol. is available at : atvbaha DOI: 10.1161 ATVBAHA.107.139626.
Luvox fluvoxamine maleate
Exposure to immediate-release fluvoxamine maleate tablets includes over 45, 000 patients treated in clinical trials and an estimated exposure of 50, 000, 000 patients treated during worldwide marketing experience end of 2005 ; . Of the 539 cases of deliberate or accidental overdose involving fluvoxamine reported from this population, there were 55 deaths. Of these, 9 were in patients thought to be taking immediate-release fluvoxamine tablets alone and the remaining 46 were in patients taking fluvoxamine along with other drugs. Among non-fatal overdose cases, 404 patients recovered completely. Five patients experienced adverse sequelae of overdosage, to include persistent mydriasis, unsteady gait, hypoxic encephalopathy, kidney complications from trauma associated with overdose ; , bowel infarction requiring a hemicolectomy, and vegetative state. In 13 patients, the outcome was provided as abating at the time of reporting. In the remaining 62 patients, the outcome was unknown. The largest known ingestion of fluvoxamine immediaterelease tablets involved 12, 000 mg equivalent to 2 to months' dosage ; . The patient fully recovered. However, ingestions as low as 1, 400 mg have been associated with lethal outcome, indicating considerable prognostic variability. In the controlled clinical trials with 403 patients treated with LUVOX CR Capsules, there was one nonfatal intentional overdose. Commonly 5% ; observed adverse events associated with fluvoxamine maleate overdose include gastrointestinal complaints nausea, vomiting, and diarrhea ; , coma, hypokalemia, hypotension, respiratory difficulties, somnolence, and tachycardia. Other notable signs and symptoms seen with immediate-release fluvoxamine maleate overdose single or multiple drugs ; include bradycardia, ECG abnormalities, such as heart arrest, QT interval prolongation, first degree atrioventricular block, bundle branch block, and junctional rhythm ; , convulsions, dizziness, liver function disturbances, tremor, and increased reflexes and endep.
Than 40 and 43 may be present on smooth muscle cells in the rat renal artery. In vivo analyses of microvessels from the brain and cremaster of the rat and arterioles from the hamster cheek pouch indicate connexins 43 and 40 are more abundant on the endothelium than the smooth muscle, suggesting greater coupling within the endothelium[27]. However connexin 43 but not connexin 37 or 40 has been demonstrated in smooth muscle cells of coronary arteries[6]. Hence, there is tissue specificity of gap junction and connexin coupling. In conclusion the present study demonstrates that in the rat renal artery EDHF-induced vasodilatations do involve gap junctions, which are sensitive to GAP 27 peptides predominantly affecting connexins 43. REFERENCES.
Is luvox available to buy in generic form and citalopram.
Gel-filled, polyurethane preemie positioning aids. Comparable to PVC and DEHP. Less toxic than PVC and DEHP.
TABLE 6. Susceptibilities to 10 drugs of 77 ampicillin- and chloramphenicol-resistant strains of H. influenzae measured by the agar dilution method Susceptibility with the following inoculum size and haldol.
Listed mania and psychosis as frequent adverse reactions. That is what the insert says for Luvox. There is no doubt in my mind that Luvox caused Eric Harris to commit these acts, " she explained.
Postmarketing reportsvoluntary reports of adverse events in patients taking luvox tablets that have been received since market introduction and are of unknown causal relationship to luvox tablets use include: ventricular tachycardia including torsades de pointes ; , porphyria, toxic epidermal necrolysis, stevens-johnson syndrome, henoch-schoenlein purpura, bullous eruption, priapism, agranulocytosis, aplastic anemia, anaphylactic reaction, angioedema, vasculitis, hyponatremia, acute renal failure, hepatitis, pancreatitis, ileus, serotonin syndrome, neuropathy, laryngismus, and severe akinesia with fever when fluvoxamine was co-administered with antipsychotic medication and fluoxetine.
Luvox 50mg for anxiety
Disorder Collier et al., 1996; Furlong et al., 1998; Hoefgen et al., 2005; Rees et al., 1997 ; , bipolar disorder Collier et al., 1996; Furlong et al., 1998; Mann et al., 2000; Rotondo et al., 2002 ; , and seasonal affective disorder Rosenthal et al., 1998 ; relative to non-psychiatric controls. Bellivier et al. 1998 ; found that patients with bipolar disorder were more likely than control subjects to be homozygous for the short allele s s genotype ; , and Ramasubbu et al. 2006 ; found that stroke patients with major depression were more likely than non-depressed stroke patients to have the s s genotype. These findings are supported by two meta-analyses Furlong et al., 1998; Lotrich & Pollock, 2004 ; , which concluded that individuals homozygous for the short allele s s genotype ; are at increased risk for both major depression and bipolar disorder. Similarly, Gonda et al. 2005 ; found that self-reported depressive symptoms were highest among s s participants and lowest among l l participants in a study of females with no history of psychiatric diagnosis, and Joiner, Johnson, Soderstrom, & Brown 2003 ; found that in a sample of non-psychiatric subjects, those with the s s genotype were more likely to have a family history of depression than those with at least one long allele. Several studies have also found that depressed patients with at least one copy of the short allele i.e., those with s l or genotypes ; demonstrate a poorer response to SSRI medications Pollock et al., 2000; Zanardi et al., 2001 ; , and at least one study has indicated that depressed s s individuals show a particularly poor response to SSRIs relative to other genotypes Smeraldi et al., 1998 ; . One study has also suggested that bipolar patients with the s s genotype are at increased risk for experiencing antidepressant-induced mania relative to bipolar patients with the l l genotype Mundo, Walker, Cate, Macciardi, & Kennedy, 2001 ; . While the association between the short allele of the serotonin transporter gene and affective disorders has been repeatedly replicated, and while literature reviews and meta-analyses generally support the existence of such an association Alda, 2001; Bellivier et al., 2002; Furlong et al., 1998; Lotrich & Pollock, 2004 ; , the literature is by no means unanimous in its support of this link. Several high-powered studies have found only non-significant trends toward an increased frequency of the short allele or the s s genotype in depressed patients relative to controls Gutierrez et al., 1998; Minov et al., 2001; Steffens et al., 2002 ; , and numerous studies have found no association between 5-HTTLPR genotype and major depression Frisch et al., 1999; Gillespie et al., 2005; Hoehe et al., 1998; Kunugi et al., 1997; Mellerup et al., 2001; Ohara, Nagai, Tsukamoto, Tani, & Suzuki, 1998; Serretti et al., 1999; Willis-Owen et al., 2005 ; , bipolar disorder Hoehe et al., 1998; Kirov et al., 1999; Kunugi et al., 1997; Mellerup et al., 2001; Mundo, Walker, Tims, Macciardi, & Kennedy, 2000; Ospina-Duque et al., 2000; Rees et al., 1997 ; , or seasonal affective disorder e.g., Johansson et al., 2001 ; . Furthermore, some studies have found results in direct contradiction to the findings reported by Lesch et al. 1996 ; . For example, Yoshida et al. 2002 ; found that in a sample of Japanese patients with major depression, the short allele was significantly more common among those who responded well to the SSRI fluvoxamine Luvox ; than among non-responders, and that all patients with the l l genotype were non-responsive to fluvoxamine treatment. Similarly, Kim et al. 2000 ; found that in a Korean sample, depressed patients with the s s genotype were more likely to respond to antidepressant treatment than were patients with other genotypes.
5 table 6 drug monitoring and contraindications medication extra monitoring for side effects contraindications maois, tricyclic antidepressants, trazodone desyrel ; , venlafaxine effexor ; bupropion wellbutrin ; , fluvoxamine luvox ; , maois, venlafaxine maois, tricyclic antidepressants, trazodone fluoxetine prozac ; , fluvoxamine, paroxetine paxil ; , tricyclic antidepressants, trazodone maois hypertensive crisis ; tricyclic antidepressants maois, nefazodone serzone ; , tricyclic antidepressants fluoxetine, fluvoxamine, sertraline zoloft ; fluoxetine, fluvoxamine, maois citalopram celexa ; , fluoxetine, fluvoxamine, mirtazapine remeron ; , nefazodone, paroxetine, sertraline, tricyclic antidepressants, trazodone, venlafaxine maois potentiate seizure risk ; tricyclic antidepressants bupropion, citalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, trazodone, venlafaxine maois, tricyclic antidepressants serotonin syndrome ; citalopram, fluoxetine, fluvoxamine, maois, mirtazapine, paroxetine, sertraline, venlafaxine maois monoamine oxidase inhibitors and paroxetine and Cheap luvox online.
SSRIs ; available today: fluoxetine Prozac ; , fluvoxamine Luvox ; , paroxetine Paxil ; , sertraline Zoloft ; , and citalo pram Celexa ; . SSRIs have in common the ability to block the reuptake of serotonin, and this functionally enhances serotoninergic activity. Fluoxetine is characterized by a long plasma half-life with a range of 1 to days and its active metabolite norfluoxetine has a half-life of up to 2 weeks. In contrast, the half-life of the other SSRIs varies between 21 hours for paroxetine and 36 hours for citalopram 93 ; . The long half-life for fluoxetine offers some pharmacoki netic advantage for patients who are less compliant with taking their medications, and fluoxetine has less of a discon tinuation syndrome compared to the shorter duration SSRIs paroxetine and sertraline 94 ; . SSRIs are inhibitors of cyto chrome P-450 isoenzymes, with paroxetine an especially strong inhibitor of the P-450-2D6 isoenzyme, whereas flu voxamine is an especially potent inhibitor of P-450-1A2. Thus there are important drugdrug interactions when SSRIs are combined with medications that are metabolized by the P-450 system. Despite their common mechanism of action, there are important pharmacokinetic and pharmaco dynamic differences. Despite their name, SSRIs are not completely selective in affecting just serotonin reuptake. For example, sertraline and to a lesser extent fluoxetine are rela tively potent dopamine reuptake inhibitors, and the various SSRIs can also block the reuptake of norepinephine 95 ; . In addition, the SSRIs also antagonize muscarinic and hista minic receptors leading to anticholinergic and sedative side effects. Of the most disturbing side effects to SSRIs, initial nausea and sexual dysfunction are the most common. Efficacy None of the SSRIs is currently approved for the treatment of alcoholism. The results of several placebo-controlled dou ble-blind studies using SSRIs for the treatment of alcohol dependence have led to conflicting results. In an Italian study with 81 subjects randomized to placebo, fluvoxamine, or citalopram, both of the SSRI groups showed a higher incidence of continuous abstinence compared to the placebo group 96 ; . Similarly, in a Finnish study of 62 randomized subjects, citalopram was more effective then placebo in alco hol drinking outcomes 97 ; . These studies are not consistent with two American trials. For example, in a 12-week trial using fluoxetine in a general sample of alcohol-dependent subjects, there were no overall differences between the medi cation and placebo groups 98 ; . At doses of up to mg per day in a group of 101 subjects who also received weekly sessions of relapse prevention therapy, fluoxetine did not reduce any measure of alcohol drinking. Although the overall results of SSRIs for alcoholism treat ment are generally negative, there may be subtypes of pa tients who benefit from treatment with SSRIs and other serotoninergic medications Table 101.3 ; . For example, in a study of 51 alcoholics with severe comorbid major depres.
Luvox prescribing information
Est MIC90s for methicillin-susceptible and -resistant S. aureus, 0.03 and 2 mg liter, respectively, in comparison with gemifloxacin 0.03 and 8 mg liter ; and moxifloxacin 0.1 and 4 mg liter ; . None of the fluoroquinolones exhibited any activity against PRVSE or penicillin- and vancomycin-resistant enterococci. Among the fluoroquinolones tested, gemifloxacin demonstrated the most potent in vitro activity against commonly encountered PSSP, PISP, and PRSP bloodstream isolates. It also had significant activity against MSSE, MRSE, S. haemolyticus, and S. hominis but was not as active as trovafloxacin against S. aureus isolates. None of the fluoroquinolones tested appears to offer any clinically important activity against penicillin-resistant enterococcal strains. An assessment of gemifloxacin's clinical utility for gram-positive coccus infections must await comparative trails in humans and trazodone.
Date: 02 25 02ISR Number: 3874259-3Report Type: Expedited 15-DaCompany Report #2002UW02017 Age: 31 YR Gender: Male I FU: I Outcome Dose Duration Hospitalization 75 mg DAILY Initial or Prolonged PO 75 mg QD PO Depressed Level Of 6 mg QD PO Consciousness 300 mg DAILY Dysarthria PO Electrocardiogram 3 DF QD Abnormal 15 mg DAILY Hypothermia PO Lung Disorder 0.75 mg QD PO Po2 Decreased 20 mg QD PO Pulmonary Infarction 150 mg QD PO Respiratory Disorder 6 mg QD PO Scintigraphy 0.5 G DAILY Somnolence PO Tachycardia Ventilation Perfusion Scan Abnormal Brovarin SS ORAL Depas SS ORAL Ravona SS ORAL Ritalin SS ORAL Halcion SS ORAL Lexotan SS ORAL Perphenazine SS ORAL Other Myonal SS ORAL Professional Wypax SS ORAL PT Blood Pressure Increased Body Temperature Decreased Report Source Foreign Literature Health Luvox SS ORAL Product Elavil Role PS Manufacturer Route ORAL.
Bpd luvox
What are the common side effects caused by Geodon? Some of the most common side effects associated with Geodon are feeling unusually tired, nausea, constipation, dizziness, restlessness, diarrhea, rash, cough and runny nose, and abnormal muscle movements, including tremor, shuffling, and uncontrollable movements. Geodon is associated with little or no weight gain in most consumers. Geodon also appears to infrequently cause increases in glucose, cholesterol, or triglyceride blood levels. Does Geodon cause tardive dyskinesia? Tardive dyskinesia TD ; is a disorder characterized by abnormal movements of the mouth, limbs, or body that occur in some people taking antipsychotic drugs. Researchers believe that atypical antipsychotics like Geodon are less likely to cause TD than the older antipsychotics. Because it may take years until researchers can fully assess the risk of TD when taking Geodon, this drug should be prescribed at the lowest effective dose to minimize that risk. If you develop symptoms of TD while taking Geodon--symptoms such as grimacing, sucking and smacking of your lips, or other abnormal movements of the body or limbs--you and your doctor should consider switching medications. Keep in mind, though, that some people may need to continue taking Geodon to most effectively control their symptoms of schizophrenia despite developing TD. What should you tell your doctor if you are considering taking Geodon? Your physician should decide if Geodon is the best treatment for you. If you are thinking about taking Geodon, be sure to tell your doctor if you: Have had any problems with your heart, have heart disease or have a family history of heart disease Have had any problems with fainting or dizziness Have had any liver problems Are pregnant or plan to get pregnant Are breastfeeding Are taking any prescription or nonprescription medications Are allergic to any medications How does Geodon interact with other medications? There are some medications that may be unsafe to use when taking Geodon, and there are some that can affect how well Geodon works. Always tell your doctor about all drugs that you are taking, including nonprescription drugs, supplements, and herbal medicines. Geodon should not be taken with any drug that affects the QT interval of the heart rhythm, such as Mellaril thioridazine ; , Quinidex quinidine ; , Avelox moxifloxicin ; , Orap pimozide ; , and Zagam sparfloxicin ; . Certain high blood pressure medications that cause low blood levels of potassium or magnesium may increase a person's risk for QT prolongation. Because Geodon has a direct effect on the central nervous system, people taking this drug should be cautious when taking other drugs that affect the central nervous system. Studies have shown that carbamazepine Tegretol; an anticonvulsant commonly used as a mood stabilizer to treat bipolar disorder ; can decrease the amount of Geodon in the body. Medications with similar effects to carbamazepine include: Sustiva efavirenz ; , Fulvicin griseofulvin ; , Mysoline primidone ; , Rezulin troglitazone ; . Studies have shown that ketoconazole Nizoral; a medication used to treat fungal infections ; can increase the amount of Geodon in the body. Medications with similar effects to ketoconazole include: Biaxin clarithromycin ; , erythromycin, Cardizem diltiazem ; , Luvox fluvoxamine ; , Prozac fluoxetine ; , Calan verapamil ; , Accolate zafirlukast.
While these are interesting cases, their complexity begs the question: how is one to keep up with all of this? Here are some "drug interaction survival tips": Become especially familiar with the properties of those medications which you prescribe or otherwise encounter on a regular basis. Pay special attention to those agents with a low therapeutic index LD50 ED50 ; , such as digoxin, lithium, and tricyclic antidepressants. Refer frequently to helpful tables, charts, drug interaction computer programs such as ePocrates Rx ProTM ; , and websites see below ; . Encourage your patients to obtain all of their medications from the same pharmacy. Sometimes it is necessary to ask the patient to specifically enroll in that pharmacy's drug interaction monitoring program, as this may not happen automatically at some commercial pharmacies. Whenever possible, select agents with less of a propensity to interact with other medications. For instance, among the selective serotonin reuptake inhibitors, fluvoxamine Luvox ; is most likely to inhibit the metabolism of other medications. Paroxetine Paxil ; and fluoxetine Prozac ; are less likely to act as significant metabolic inhibitors, but this is still very much an issue with these agents. Sertraline Zoloft ; has even less of an inhibitory profile, but this can become more of an issue at the higher dose range for this drug. Citalopram Celexa ; and escitalopram Lexapro ; , however, lack the ability to significantly inhibit any of the P450 enzymes. There are a couple of books which address these topics. First, there is the Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450, UGTs, P-Glycoprotein by Kelly Cozza, MD, Scott Armstrong, MD, and Jessica Oesterheld, MD. This book examines these systems in a thorough manner, starting with the basic physiologic features of these systems and then exploring areas of clinical interest. It also contains chapters that address the drug interactions which may arise in particular medical subspecialties internal medicine, neurology, infectious diseases, etc. ; . I have also written a book entitled the Drug Interactions Casebook: The Cytochrome P450 System and Beyond, which is a collection of 177 clinical case vignettes illustrating the wide variety of drug interactions, accompanied by explanations of why the interactions occurred. The two cases discussed in this article are from my book. Both books are available through American Psychiatric Press, Inc. appi ; . I hope this is a helpful review of this topic which will encourage proactive prevention and not therapeutic paralysis. Good luck and first do no harm.
Collins 1951 ; exposed female guinea pigs, and Cameron 1951 ; exposed male guinea pigs twice daily to 100% natural gas atmospheres for approximately 40 sec to unconsciousness, never over 2 min ; . One animal a week was killed for microscopic study of the ovaries and testes. The authors reported functional reproductive failure in male guinea pigs exposed to natural gas for regular brief periods, and the pathology confirmed reversible cellular changes in both males testes ; and females ovaries ; . No asphyxiant studies on control gases were performed. A unique way to study the toxicity of natural gas was reported by Volesky et al. 1975 ; . Rats were fed diets containing high protein fungus grown on natural gas for up to 40% of diet for 1 week and up to 20% of diet for 5 months. Growth was slower when virtually all dietary protein was furnished by the fungus instead of casein, but the animals appeared normal and healthy. Deinega 1972 ; reported in the Russian literature the exposure of rats, guinea pigs, and dogs to "mine gas" containing 92.6% methane, 4.2% ethane, propane 1%, butane 1%, and nitrogen, hydrogen, and krypton, 2.15% total. The only effect noted was anoxia and decreased frequency of respiration during exposure. In a study of the minor constituents of cigarette smoke on the cells of the cat trachea, Weissbecker et al. 1971 ; reported that methane reversed the drying effect of some smoke components and increased the mucus 'flow, approaching that seen in the unexposed animal. Morozova 1963 ; , in the Russian literature, performed experimental studies on rats exposed to carbon monoxide alone and carbon monoxide in combination with methane 70%. In the liver, changes occurring with carbon monoxide combined with methane increase in hepatic cell nuclei size, lobular fatty degeneration, distrophy of the liver parenchyma ; are less profound than when exposure to carbon monoxide alone is practiced. Therefore, it was concluded that methane does not cause any structural alterations in the liver of rats and that it lessens the effects of carbon monoxide. Burrell and Oberfell in an undated report for the U.S. Bureau of Mines about 1915 ; discussed the effects of natural gas on canaries. When the birds were exposed to natural gas in a 10-liter bell jar, as much as 63% natural gas did not produce collapse within 1 hr although distress was immediate. The authors describe distress in the birds as open bills, breathi n g r and squatting on the perch in a lethargic manner * Some deaths occurred at 65% natural gas in air. The deaths were due to oxygen deficiency in the canaries, not to any toxic effect of the gas!
| Luvox erowidAntidepressants in clinical trials. A large Danish study run by the Danish University Antidepressant Group later confirmed thisxli. This was at a time when the size of the non-hospital depression market still appeared relatively small. It was, therefore, not obvious how a less effective antidepressant, even if it were safer, could be expected to take a significant share in this market. The clinical development of paroxetine accordingly lagged way behind that of Zelmid and Indalpine and considerably behind that of Luvox and Prozac. Paroxetine ended up being licensed as Paxil in 1993 in the United States and Seroxat in 1992 in the United Kingdom. As part of the effort to make up ground on the others, marketers within what was now SmithKline Beecham coined the acronym SSRI. Compared to the other serotonin reuptake inhibitors, paroxetine was supposedly the selective serotonin reuptake inhibitor the SSRIxlii. The name worked -- too well. It was adopted for the entire group of compounds. In this way, Paxil made Prozac and Zoloft into SSRIs. The idea of an SSRI conveys the impression of a clean and specific drug that would be freer of side effects than the non-selective TCAs. However, selectivity for pharmacologists and selectivity for clinicians meant different things. For pharmacologists, an SSRI might act on every brain system other than the norepinephrine system and therefore might be in this sense an even dirtier drug than any of the TCAs. Clinicians were misled if they thought that selective meant that these drugs only acted on one brain site, but this was exactly what the marketing of these drugs suggested to clinicians. Where Upjohn had targeted OCD in an effort to carve out a distinctive identity for Luvox, SmithKline targeted panic disorder, anxious depressions, generalized anxiety disorder and social phobia. When the company got a license to market Paxil for social phobia, its stock rose; an anti-shyness pill was potentially a huge market. Social phobia had until the 1990s been a condition that was almost unknown in the Western worldxliii. First described in the 1960s at the Institute of Psychiatry in London by Isaac Marks, social phobia presented rarely to clinics. It would be a mistake to think that SmithKline somehow invented social phobia because in the Far East it appears that social phobias are the most common nervous condition. But there is clearly an overlap between social phobia and shyness. As a consequence, there is a real risk that and buy keppra.
At this time, there are five different SSRI antidepressants available in the United States. They are Prozac fluoxetine is generic name ; , Zoloft sertraline ; , Paxil paroxetine ; , Celexa citalopram ; and Luvox fluvoxamine ; . Studies have shown that all of them work about the same and produce the same amount of side effects. Prozac is the only SSRI that has a generic version available currently.
Retractile mesenteritis is a rare inflammatory condition of unknown cause, in which the fat of the mesentery is finally replaced by fibrotic tissue. The process usually involves the mesentery of the small bowel, but can occasionally involve the mesocolon and in rare occasions the peripancreatic region, omentum, retroperitoneum and pelvis [1]. The etiology of this disorder is unknown: the use of drugs, infection, autoimmunity, trauma, malignancy, prior abdominal surgery and local ischemia have been suggested as possible causative factors [1-4].
Luvox products
|
Her doctor says that there shouldn't be a problem with taking coumadin, luvox and klonopin-yet, in my recent research, i saw that there is a high clinical possibility for interaction between luvox and warfarin.
Luvox F150 is also available without touchscreen. The non-touch model is fitted with a protective glass filter for protection of the LCD panel. It also has composite video and S-video inputs.
Positively Aware will treat all communications letters, faxes, e-mail, etc. ; as letters to the editor unless otherwise instructed. We reserve the right to edit for length, style or clarity. Please advise if we can use your name and city. Editor's note: Sero-sorting is a term that refers to the practice of choosing one's sexual partners based on their HIV status, generally used as a prevention tool. For instance, an HIV-positive individual may choose to have sex with only other HIVpositive partners, while an HIV-negative person may choose only negative partners. However, it is by no means a fool-proof method for those who are negative to stay that way. There is a window period of up to six months after an unsafe encounter before antibodies to HIV may show up in a blood test. ould you let Jack know I really enjoyed his piece on serosorting? It was a nice combination of personal feelings and information. I wrote a similar piece in ACRIA Update's Summer issue, so I know how he feels. See acria treatment treatment edu summerupdate2007 ub2. html. If enough of us keep speaking, maybe the word will finally get out! Write to: Positively Aware, 5537 North Broadway Chicago, IL 60640 Fax: 773 ; 9899494 E-mail: readersforum tpan.
Luvox fda indications
Randomised, double blind, placebo controlled trial with 1 year follow up.
Luvox nightmares
Luvod, lufox, luvos, luvlx, lugox, luv0x, lvox, lluvox, luvxo, lvuox, luuvox, luox, livox, luovx, puvox, luvvox, luvx, lubox, uvox.
Luvox children
Luvox thyroid, luvox fluvoxamine maleate, luvox 50mg for anxiety, luvox prescribing information and bpd luvox. Luvox erowid, luvox products, luvox fda indications and luvox nightmares or luvox children.
Luvox no weight gain
Hnpcc histology, bronchiolitis children, flood jars of clay tab, myelin and autism and blastomycosis more alternative_medicine. Erythromycin phosphate, eyelid not opening fully, appendix j of the fact act and antagonist in a rose for emily or cognitive heart disease.
|
